http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MA-34285-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C321-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate | 2011-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ba5004655b4b776e2686fd48a150f7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7004cc50c22575b49e312a0750913379 |
| publicationDate | 2013-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MA-34285-B1 |
| titleOfInvention | TREATMENT OF AUTOIMMUNE DISEASES |
| abstract | The invention relates to the use of a compound of Formula I in which X is O, S, SO or SO 2; R 1 represents a halogen or a trihalogenomethyl group, -OH, C1-C7 alkyl, C1-4 alcohoxyl, trifluoromethyloxy, phenoxy, cyclohexylmethyloyloxy, pyrimethylmethyl, quinamyloxy, naphthylmethyl, phenoxymethyl, -CH2-OH, -CH2-CH2-OH, C1-4 ALKYLTHIO, C1-4 ALKYLSULFINYL, C1-4 ALKYLSULFONYL, BENZYLTHIO, ACETYL, NITRO OR CYANO OR A PHENYL GROUP, PHENYL (C1-4 ALKYL) OR PHENYL (C1-4 ALCOXY), EACH OF WHICH PHENYL GROUP IS POSSIBLY SUBSTITUTED BY A HALOGEN OR GROUP CF3, C1-4 ALKYL OR C1-4 ALCOXY; R2 is H, a halogen or a trihalogenomethyl group, C1-4 alkoxy, C1-7 alkyl, phenylthyl or benzyloxy; R3 represents H, a halogen or a group CF3, OH, C1-7alkyl, C1-4alkoxy, benzoyloxy, phenyl or (C1-4alkyl) methylyl; EACH OF R4 AND R5 IS INDEPENDENTLY H OR A RESIDUE OF FORMULA (A) IN WHICH EACH OF R8 AND R9 REPRESENTS, INDEPENDENTLY, H OR A C 1-4 ALKYL GROUP POSSIBLY SUBSTITUTED BY HALOGEN; AND N REPRESENTS AN ENTIER FROM 1 TO 4; OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, ISOMER OR PRODUCT THEREOF; OR A COMPOUND OF FORMULA II IN WHICH R1A REPRESENTS A HALOGEN OR A TRIHALOGENOMETHYL GROUP, C1-4 ALKYL, C1-4 ALCOXY, C1-4 ALKYLTHIO, C1-4 ALKYLSULFINYL, C1-4 ALKYLSULFONYL, ARALKYL , PHENOXY POSSIBLY SUBSTITUTED OR ARALKYLOXY; R2A REPRESENTS H, A HALOGEN OR TRIHALOGENOMETHYL GROUP, C1-4 ALKYL, C1-4 ALCOXY, ARALKYL OR ARALKYLOXY; R3A REPRESENTS H, A HALOGEN OR A GROUP CF3, C1-4 ALKYL, C1-4 ALCOXY, C1-4 ALKYLTHIO OR BENZYLOXY; R4A REPRESENTS H OR A C 1-4 ALKYL GROUP, PHENYL, BENZYL OR BENZOYL GROUP SUBSTITUTED OR ACYLIC C 1-5 LOWER ALIPHATIC; R5A REPRESENTS H OR A MONOHALOGENOMETHYL, C1-4 ALKYL, (C1-4 ALCOXY) METHYL, (C1-4 ALKYL) THIOMETHYL, HYDROXYMETHYL, HYDROXYPROPYL, PHENYL, ARALKYL, C2-4 ALKENYL OR C2-ALKYNYL 4; R6A REPRESENTS H OR A C1-4 ALKYL GROUP; R7A REPRESENTS H, A C1-4 ALKYL GROUP OR A FORMULA RESIDUE (A) AS DEFINED ABOVE; XA REPRESENTS O, S, SO OR SO2; AND NA REPRESENTS AN ENTIER FROM 1 TO 4; OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, ISOMER OR PRODUCT THEREOF; IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OR PROPHYLAXIS OF SUBSIDUATED SKIN LUPUS ERYTHEMATOUS (SCLE) AND RELATED AUTOIMMUNE SKIN DISORDERS. |
| priorityDate | 2010-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.